Shen Y, Cai R, Sun J et al (2017) Diabetes mellitus as a risk factor for incident chronic kidney disease and end-stage renal disease in women compared with men: a systematic review and meta-analysis. Endocrine 55(1):66–76. https://doi.org/10.1007/s12020-016-1014-6

Article  PubMed  CAS  Google Scholar 

Peters SA, Huxley RR, Woodward M (2014) Diabetes as risk factor for incident coronary heart disease in women compared with men: a systematic review and meta-analysis of 64 cohorts including 858,507 individuals and 28,203 coronary events. Diabetologia 57(8):1542–1551. https://doi.org/10.1007/s00125-014-3260-6

Article  PubMed  Google Scholar 

Peters SA, Huxley RR, Woodward M (2014) Diabetes as a risk factor for stroke in women compared with men: a systematic review and meta-analysis of 64 cohorts, including 775,385 individuals and 12,539 strokes. Lancet 383(9933):1973–1980. https://doi.org/10.1016/S0140-6736(14)60040-4

Article  PubMed  Google Scholar 

American Diabetes Association (2021) 10. Cardiovascular Disease and Risk Management: Standards of Medical Care in Diabetes-2021. Diabetes Care 44(Suppl 1):S125–S150. https://doi.org/10.2337/dc21-S010

Article  Google Scholar 

Kidney Disease: Improving Global Outcomes (KDIGO) Diabetes Work Group (2020) KDIGO 2020 clinical practice guideline for diabetes management in chronic kidney disease. Kidney Int 98(4S):S1–S115. https://doi.org/10.1016/j.kint.2020.06.019

Article  Google Scholar 

Hilliard LM, Sampson AK, Brown RD, Denton KM (2013) The “his and hers” of the renin-angiotensin system. Curr Hypertens Rep 15(1):71–79. https://doi.org/10.1007/s11906-012-0319-y

Article  PubMed  CAS  Google Scholar 

Komukai K, Mochizuki S, Yoshimura M (2010) Gender and the renin-angiotensin-aldosterone system. Fundam Clin Pharmacol 24(6):687–698. https://doi.org/10.1111/j.1472-8206.2010.00854.x

Article  PubMed  CAS  Google Scholar 

Rabi DM, Khan N, Vallee M, Hladunewich MA, Tobe SW, Pilote L (2008) Reporting on sex-based analysis in clinical trials of angiotensin-converting enzyme inhibitor and angiotensin receptor blocker efficacy. Can J Cardiol 24(6):491–496. https://doi.org/10.1016/S0828-282X(08)70624-X

Article  PubMed  PubMed Central  CAS  Google Scholar 

Trenkwalder P, Elmfeldt D, Hofman A et al (2005) The Study on COgnition and Prognosis in the Elderly (SCOPE) - major CV events and stroke in subgroups of patients. Blood Press 14(1):31–37. https://doi.org/10.1080/08037050510008823

Article  PubMed  Google Scholar 

Kizer JR, Dahlöf B, Kjeldsen SE et al (2005) Stroke reduction in hypertensive adults with cardiac hypertrophy randomized to losartan versus atenolol: the Losartan Intervention For Endpoint reduction in hypertension study. Hypertension 45(1):46–52. https://doi.org/10.1161/01.HYP.0000151324.05355.1c

Article  PubMed  CAS  Google Scholar 

Zanchetti A, Julius S, Kjeldsen S et al (2006) Outcomes in subgroups of hypertensive patients treated with regimens based on valsartan and amlodipine: an analysis of findings from the VALUE trial. J Hypertens 24(11):2163–2168. https://doi.org/10.1097/01.hjh.0000249692.96488.46

Article  PubMed  CAS  Google Scholar 

Turnbull F, Woodward M, Neal B et al (2008) Do men and women respond differently to blood pressure-lowering treatment? Results of prospectively designed overviews of randomized trials. Eur Heart J 29(21):2669–2680. https://doi.org/10.1093/eurheartj/ehn427

Article  PubMed  Google Scholar 

Brenner BM, Cooper ME, de Zeeuw D et al (2001) Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 345(12):861–869. https://doi.org/10.1056/NEJMoa011161

Article  PubMed  CAS  Google Scholar 

Brenner BM, Cooper ME, de Zeeuw D et al (2000) The losartan renal protection study–rationale, study design and baseline characteristics of RENAAL (Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan). J Renin Angiotensin Aldosterone Syst 1(4):328–335. https://doi.org/10.3317/jraas.2000.062

Article  PubMed  CAS  Google Scholar 

Lewis EJ, Hunsicker LG, Clarke WR et al (2001) Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 345(12):851–860. https://doi.org/10.1056/NEJMoa011303

Article  PubMed  CAS  Google Scholar 

Rodby RA, Rohde RD, Clarke WR et al (2000) The Irbesartan type II diabetic nephropathy trial: study design and baseline patient characteristics. For the Collaborative Study Group. Nephrol Dial Transplant 15(4):487–497. https://doi.org/10.1093/ndt/15.4.487

Article  PubMed  CAS  Google Scholar 

Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D (1999) A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 130(6):461–470. https://doi.org/10.7326/0003-4819-130-6-199903160-00002

Article  PubMed  CAS  Google Scholar 

Young JB, Dunlap ME, Pfeffer MA et al (2004) Mortality and morbidity reduction with candesartan in patients with chronic heart failure and left ventricular systolic dysfunction: results of the CHARM low-left ventricular ejection fraction trials. Circulation 110(17):2618–2626. https://doi.org/10.1161/01.CIR.0000146819.43235.A9

Article  PubMed  CAS  Google Scholar 

Cohn JN, Tognoni G, Valsartan Heart Failure Trial Investigators (2001) A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med 345(23):1667–1675. https://doi.org/10.1056/NEJMoa010713

Article  PubMed  CAS  Google Scholar 

Israili ZH (2000) Clinical pharmacokinetics of angiotensin II (AT1) receptor blockers in hypertension. J Hum Hypertens 14(Suppl 1):S73–S86. https://doi.org/10.1038/sj.jhh.1000991

Article  PubMed  CAS  Google Scholar 

Food and Drug Administration (FDA) Drug Prescribing Information. Atacand (candesartan Cilexetil) prescribing information. Available online at: https://www.drugs.com/pro/atacand.html. Accessed 20 July 2023

Food and Drug Administration (FDA) Drug Prescribing Information. Diovan (valsartan) prescribing information. Available online at: https://www.drugs.com/pro/diovan.html. Accessed 20 July 2023

Food and Drug Administration (FDA) Drug Prescribing Information. Avapro (irbesartan) prescribing information. Available online at: https://www.drugs.com/pro/avapro.html. Accessed 20 July 2023

Food and Drug Administration (FDA) Drug Prescribing Information. Cozaar (losartan potassium) prescribing information. Available online at: https://www.drugs.com/pro/cozaar.html. Accessed 20 July 2023

Albertus P, Morgenstern H, Robinson B, Saran R (2016) Risk of ESRD in the United States. Am J Kidney Dis 68(6):862–872. https://doi.org/10.1053/j.ajkd.2016.05.030

Article  PubMed  PubMed Central  Google Scholar 

Wilkins JT, Ning H, Berry J, Zhao L, Dyer AR, Lloyd-Jones DM (2012) Lifetime risk and years lived free of total cardiovascular disease. JAMA 308(17):1795–1801. https://doi.org/10.1001/jama.2012.14312

Article  PubMed  PubMed Central  CAS  Google Scholar 

Ricardo AC, Yang W, Sha D et al (2019) Sex-related disparities in CKD progression. J Am Soc Nephrol 30(1):137–146. https://doi.org/10.1681/ASN.2018030296

Article  PubMed  CAS  Google Scholar 

Shajahan S, Amin J, Phillips JK, Hildreth CM (2021) Relationship between sex and cardiovascular mortality in chronic kidney disease: a systematic review and meta-analysis. PLoS One 16(7):e0254554. https://doi.org/10.1371/journal.pone.0254554

Article  PubMed  PubMed Central  CAS  Google Scholar 

Sullivan JC (2008) Sex and the renin-angiotensin system: inequality between the sexes in response to RAS stimulation and inhibition. Am J Physiol Regul Integr Comp Physiol 294(4):R1220–R1226. https://doi.org/10.1152/ajpregu.00864.2007

Article  PubMed  CAS  Google Scholar 

Medina D, Mehay D, Arnold AC (2020) Sex differences in cardiovascular actions of the renin-angiotensin system. Clin Auton Res 30(5):393–408. https://doi.org/10.1007/s10286-020-00720-2

Article  PubMed  PubMed Central  Google Scholar 

Phipps AI, Ichikawa L, Bowles EJ et al (2010) Defining menopausal status in epidemiologic studies: a comparison of multiple approaches and their effects on breast cancer rates. Maturitas 67(1):60–66. https://doi.org/10.1016/j.maturitas.2010.04.015

Article  PubMed